Paper Details

  1. Home
  2. Paper Details

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.

Author: ChenTing, DengXiaojuan, GaoLei, KongPeiyan, LiJieping, RaoJun, TanXu, YaoHan, YinXiaolin, ZhangCheng, ZhangXi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A retrospective analysis of 110 refractory and relapsed acute myeloid leukemia (r/rAML) patients compared the efficacy and toxicity of CLAG+PLD to CLAG alone as salvage therapy. The study found that the addition of PLD to CLAG resulted in a higher complete remission rate and longer overall survival.
Paper Details　
Original Abstract of the Article :
Refractory and relapsed acute myeloid leukemia (r/rAML) is associated with a difficult prognosis; clinical trials are typically suggested despite lack of a recognized standard of care. Combinatorial chemotherapy regimens utilized for r/rAML salvage play a crucial role in battling this invasive phase...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278524/

データ提供：米国国立医学図書館（NLM）

Combating Refractory and Relapsed Acute Myeloid Leukemia: Exploring New Treatment Strategies

The fight against [acute myeloid leukemia (AML)] is an ongoing battle, and researchers are constantly seeking new ways to improve [treatment] outcomes. This study investigates the efficacy and toxicity of [CLAG combined with pegylated liposomal doxorubicin (PLD)] for [refractory or relapsed AML]. It's like searching for a hidden treasure in the vast desert of [cancer research], hoping to find a cure for this devastating disease.

A Comparative Analysis of CLAG and CLAG+PLD

The study retrospectively analyzed data from [110 patients] with [refractory or relapsed AML], comparing [CLAG+PLD] to [CLAG alone]. It's like comparing two different paths through the desert, seeking the one that leads to the best outcome. The authors evaluated [response rates, overall survival (OS), disease-free survival (DFS), and side effects] to determine the optimal treatment approach.

Hope for Improved Treatment Outcomes in Refractory and Relapsed AML

The findings of this study could pave the way for more effective [treatment] strategies for [refractory or relapsed AML]. It's like finding a wellspring of hope in the arid landscape of [cancer treatment]. Further research is needed to confirm these preliminary findings, but the results are promising for patients battling this challenging condition.

Dr.Camel's Conclusion

This research is like a journey through a desert, where each step brings us closer to a cure for [refractory or relapsed AML]. The authors' dedication to finding better [treatment] options is a testament to the resilience of the medical community in facing this challenging disease.

Date :
  1. Date Completed 2023-06-20
  2. Date Revised 2023-06-21
Further Info :

Pubmed ID

37161845

DOI: Digital Object Identifier

PMC10278524

Related Literature

Article Analysis
・Side Effects of cytarabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.